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Abstract
Background—Sublingual immunotherapy (SLIT) with peanut changes clinical and immune 
responses in most peanut-allergic individuals, but the response is highly variable.
Objective—We sought to examine the component-specific effects of peanut SLIT and determine 
whether peanut component testing could predict the outcome of a double-blind, placebo-controlled 
food challenge (DBPCFC) after 12 months of peanut SLIT.
Methods—We included 33 subjects who underwent peanut SLIT with a DBPCFC of 2500 mg of 
peanut protein performed after 12 months on therapy. Plasma samples from baseline and after 12 
months of peanut SLIT were assayed using ImmunoCAP for IgE and IgG4 against whole peanut, 
Ara h 1, Ara h 2, Ara h 3, Ara h 8, and Ara h 9.
Results—Following 12 months of SLIT, 10 subjects (30%) passed the DBPCFC without 
symptoms and were considered desensitized. Subjects that failed the DBPCFC tolerated a median 
of 460 mg peanut protein (range: 10–1710 mg). The desensitized group had significantly lower 
baseline levels of IgE against peanut (median 40.8 vs 231 kUA/L, p = 0.0082), Ara h 2 (median 17 
vs 113 kUA/L, p=0.0082), and Ara h 3 (median 0.3 vs 8.5 kUA/L, p = 0.0396). ROC curves 
indicated that baseline IgE against peanut and Ara h 2 were equally effective at discriminating 
between the two groups (AUC = 0.7957, p = 0.007752 for both).
Conclusion and Clinical Relevance—In this cohort of subjects undergoing SLIT for peanut 
allergy, lower baseline levels of IgE against Ara h 2, Ara h 3, and peanut were associated with 
successful desensitization.
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INTRODUCTION
Peanut allergy is a public health concern affecting greater than 1% of the US population.1 
Reactions to peanut can be life threatening,2 and peanut-allergic patients and their families 
experience diminished quality of life.3 There are no available treatments for peanut allergy, 
and the current standard of care involves strict avoidance of peanut and access to self-
injectable epinephrine. Our group and others are actively conducting clinical trials to 
determine the safety and efficacy of immunotherapy for the treatment of peanut allergy.4, 5
One approach under investigation is sublingual immunotherapy (SLIT), which involves 
daily administration of micrograms of peanut protein extract under the tongue. Although 
safe, clinical responses to peanut SLIT are highly variable, ranging from complete response 
in a minority of subjects, to others that do no better than placebo.6,7 Previous studies have 
shown that SLIT modulates IgE and IgG4 specific to whole peanut,6 and that peanut-
specific IgE and salivary IgA at the time of challenge may correlate with amount of protein 
ingested in a double-blind placebo-controlled food challenge (DBPCFC) after 12 months of 
therapy. 6, 8 These end-of-therapy measures, however, cannot aid in the selection of SLIT 
subjects. Given the substantial heterogeneity in treatment responses, it would be a major 
advance to develop predictors of outcome to optimize the selection of individuals most 
likely to benefit prior to engaging in immunotherapy.
With the recent introduction of ImmunoCAP tests specific for the peanut component 
antigens Ara h 1, 2, 3, 8, and 9, there has been increased interest in the measurement of 
component-specific immunoglobulins as a way to improve peanut allergy diagnosis. Several 
studies have shown that Ara h 2-specific IgE can be useful in diagnosing peanut allergy,9–15 
and that patients monosensitized to Ara h 8 may be clinically tolerant.16,17 While Ara h 1, 2, 
and 3 may be the major allergens in the United States, others have shown that component 
sensitization can vary by region; Ara h 9 appears to predominate in peanut-allergic patients 
in Spain and the Mediterranean18,19 and Ara h 8 predominates in the Swedish population.19 
With the current evidence, component-specific testing is likely only relevant to clinical 
decision-making in specific situations.20
In this study, we sought to use component-specific analyses to examine for the first time the 
effects of SLIT on antibody reactivity to individual peanut allergens, and to determine if 
specific binding patterns could serve as a biomarker for clinical outcomes following peanut 
SLIT. We measured peanut- and peanut component-specific IgE and IgG4 in subjects who 
underwent 12 months of peanut SLIT followed by a DBPCFC to assess desensitization. We 
hypothesized that subjects with lower baseline IgE against the major peanut allergens, Ara h 
1, 2, and 3, would be more likely to achieve desensitization than those with highly elevated 
IgE against the major allergens.
METHODS
SLIT Subjects
Plasma samples obtained from blood collected in sodium-heparin-containing tubes from 33 
subjects on peanut SLIT were available for use in this study. 18 out of 33 subjects were 
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enrolled in a previously described randomized, placebo-controlled trial of SLIT for peanut 
allergy,6 11 of whom were in the original, blinded treatment arm, and 7 of whom crossed-
over and underwent open-label peanut SLIT after 12 months of sham treatment. Food 
challenge outcomes for an additional 9 who underwent open-label treatment have been 
previously reported,21 and 6 subjects who underwent open-label treatment are presented 
here for the first time. This study was approved by the Institutional Review Boards of Duke 
University and the University of North Carolina.
Subjects (1–11 years old at time of enrollment) had an initial peanut CAP-FEIA greater than 
7 kUA/L and a clinical history of reaction to peanut. Baseline food challenges were not 
performed. Over 6 months of biweekly visits, subjects were built up from an initial daily 
dose of 0.25 mcg of peanut protein to a maintenance dose of 2000 mcg per day. After 6 
additional months of maintenance dosing, subjects underwent a DBPCFC to 2500 mg of 
peanut protein. Plasma samples from 0 months of peanut SLIT and following 12 months of 
peanut SLIT were kept frozen at −20°C until time of analysis.
ImmunoCAP
Peanut- and peanut component-specific IgE and IgG4 were measured via ImmunoCAP 100 
(Thermo Fisher, Uppsala, Sweden) according to the manufacturer’s specifications.
Statistical Analysis
If a sample had a measured IgE or IgG4 below the lower limit of detection (0.01 kUA/L for 
IgE or 0.001 mgA/L for IgG4), based on previous work,22 a value of half of this lower limit 
(0.005 kUA/L for IgE or 0.0005 mgA/L for IgG4) was used in statistical analyses, IgE/IgG4 
calculations, and figures. Wilcoxon signed-rank tests for longitudinal tests, Mann-Whitney 
U for between-group tests, ROC curves, and simple linear regression analyses were 
calculated with GraphPad Prism 5 (La Jolla, CA). A p-value < 0.05 was considered 
significant.
RESULTS
Food Challenge Outcomes
10/33 (30%) subjects completed the 2500 mg food challenge without symptoms and were 
considered fully desensitized. The remaining 23 subjects tolerated a median of 460 mg, with 
a range of 10–1710 mg (Figure 1).
After 12 months of SLIT, peanut- and component-specific IgE remained stable, sIgG4 
increased, and the sIgE/sIgG4 ratio decreased
Compared to baseline, Ara h 1-, Ara h 2-, Ara h 3-, and peanut-sIgE were not significantly 
different after 12 months of SLIT (Figure 2A). Ara h 8- and Ara h 9-specific IgE increased 
significantly (Medians, kUA/L: Ara h 8: 0.05 to 0.12, p <0.0001; Ara h 9: 0.05 to 0.17, p = 
0.0018; see Online Supplemental Figure 1A for all data including IQR), but the median 
specific IgE stayed below 0.35 kUA/L. As shown in Figure 2B, specific IgG4 to peanut and 
all components significantly increased after 12 months of SLIT (Medians, mgA/L: Ara h 1: 
0.127 to 0.905, p <0.0001; Ara h 2: 0.23 to 2.24, p <0.0001; Ara h 3: 0.154 to 0.156, p = 
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0.0038; Ara h 8: 0.029 to 0.054, p = 0.0184; Ara h 9: 0.027 to 0.096, p <0.0001; Peanut: 
0.787 to 4.47, p <0.0001; see Online Supplemental Figure 1A for all data including IQR). 
The specific IgE/specific IgG4 ratio decreased from baseline for Ara h 1, Ara h 2, Ara h 3, 
and peanut (Figure 2C) (Medians: Ara h 1: 258 to 20.44, p <0.0001; Ara h 2: 322 to 9.5, p 
<0.0001; Ara h 3: 12 to 9.32, p = 0.0003; Peanut: 119.9 to 13.66, p <0.0001; see Online 
Supplemental Figure 1A for all data including IQR). Specific IgE/specific IgG4 was not 
significantly different for Ara h 8 and Ara h 9.
Baseline measurements were significantly different between passing and failing subjects
At baseline, Ara h 2-, Ara h 3-, and peanut-specific IgE were significantly higher in subjects 
who ultimately failed the 12 month food challenge (Medians, kUA/L: Ara h 2: median 17.0 
vs 113, p = 0.0082; Ara h 3: 0.3 vs 8.5, p = 0.0396 Peanut: 40.8 vs 231, p = 0.0082; Figure 
3A). As shown in Figure 3B, Ara h 8-specific IgG4 was significantly higher in the failing 
group (median 0.145 vs 0.063 mgA/L, p = 0.0349). Specific IgE/specific IgG4 ratios for the 
peanut antigens were not different between the groups that passed or failed the DBPCFC, 
but the peanut-specific IgE/peanut-specific IgG4 was significantly higher in those who 
failed the food challenge (median 55.87 vs 199.8 p = 0.0096, Figure 3C). See Online 
Supplemental Figure 1B for all data including IQR. IgE, IgG4, and IgE/IgG4 specific to 
peanut and the peanut antigens in samples from the time of the 12 month food challenge 
showed no significant differences between the two groups. (data not shown).
Discriminating between subjects that passed and failed the desensitization challenge
Only baseline values could differentiate between subjects passing and failing the 
desensitization challenge. The ROC analyses are shown in Figure 4. Peanut- and Ara h 2-
sIgE were the best at discriminating between passing and failing groups (AUC = 0.7957, p = 
0.007752), and optimal cut points for these discriminations were >81.30 kUA/L (65.22% 
sens., 90% spec.) for peanut-sIgE, >48.55 kUA/L (65.22% sens., 90% spec.) for Ara h 2-
sIgE. Peanut-sIgE/IgG4 (AUC = 0.7826, p = 0.01092), Ara h 8-sIgG4 (AUC = 0.7326, p = 
0.03615), and Ara h 3-sIgE (AUC = 0.7304, p = 0.03793) did not discriminate as well 
between the two groups. In addition, linear regression analyses considering amount ingested 
at challenge and IgE, IgG4, or IgE/IgG4 at baseline or at the time of challenge found no 
significant correlations (data not shown).
DISCUSSION
As reported here and in our previous publication,6 food challenge outcomes were variable 
after 12 months of peanut SLIT. These outcomes are in contrast to oral immunotherapy 
(OIT), in which participants ingest a maintenance dose 2000-fold larger than the dose used 
in SLIT, and a majority of subjects are able to pass a DBPCFC after 12 months of therapy.21 
SLIT, however, may be easier to tolerate than OIT because of the smaller daily dose, 
sublingual administration, fewer allergic side effects, and liquid rather than flour vehicle.6 It 
would be useful, then, to find a parameter associated with successful desensitization so that 
appropriate subjects could be selected to receive SLIT. We used a component-resolved 
analysis to elucidate whether there are differences in peanut- and component-specific 
immunoglobulins between subjects passing and failing a DBPCFC following SLIT.
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In our analysis, we measured IgE and IgG4 specific to Ara h 1, 2, 3, 8, 9 and peanut at 
baseline and after 12 months of SLIT. We found that specific IgG4 to all components and 
peanut significantly increased, and that the IgE/IgG4 ratio significantly decreased for Ara h 
1, 2, 3, and whole peanut. We did not observe any significant changes in specific IgE to Ara 
h 1, 2, 3, and peanut, and specific IgE to Ara h 8 and 9 did not reach levels above 0.35 
kUA/L, the value considered clinically significant. These results are consistent with previous 
findings regarding SLIT’s effect on peanut-specific IgE and specific IgG4,6 and show that 
the effect on IgE/IgG4 ratio was found only for Ara h 1, 2, 3, and whole peanut, but not Ara 
h 8 or 9. Our results with sublingual immunotherapy are also similar to those reported in a 
recent study of the humoral response to Ara h 1, 2, and 3 in Japanese children receiving 
peanut oral rush immunotherapy, in which the authors found an increase in IgG4 against Ara 
h 1, 2, 3 after 12 months of oral immunotherapy and no change in specific IgE against these 
components.23 The study, however, did not include certain elements of our study, such as 
food challenges to evaluate the effectiveness of therapy, and subjects sensitized to Ara h 8 or 
9.
Our results may indicate that SLIT primarily modulates the humoral response, specifically 
the IgE/IgG4 ratio, to the three major allergens. They may, however, represent the 
sensitization profiles typically seen in U.S. patients with known systemic peanut allergy.19 
The extent to which immunotherapy may alter allergen-specific immune responses does also 
depend on the amount of major allergen present in the treatment extract.
Comparing subjects who passed and failed the 12 month food challenge, we found that Ara 
h 2-, 3-, and peanut-specific IgE, Ara h 8-specific IgG4, and peanut-specific IgE/specific 
IgG4 were all higher at baseline in failing subjects. Using ROC curves to discriminate 
between the two groups, we found, based on the AUC, that peanut- and Ara h 2-specific IgE 
were equally effective at predicting the outcome of the food challenge, and that Ara h 8-
specific IgG4 and Ara h 3-specific IgE were less effective. The optimal cut point for peanut-
specific IgE was >81.30 kUA/L (69.57% sens., 90% spec.) and the cut point for Ara h 2-
specific IgE was >48.55 kUA/L (65.22% sens., 90% spec.). Interestingly, these cut points are 
similar to those reported by Vickery et al. (peanut-specific IgE >85.5 kUA/L and Ara h 2-
specific IgE >35.5 kUA/L) to discriminate between those who did and did not exhibit 
sustained unresponsiveness following long-term OIT. We do think it is important to note, 
however, that the present study is limited to the examination of outcomes after 12 months of 
continuous peanut SLIT treatment, and does not concern tolerance or sustained 
unresponsiveness in these subjects following cessation of treatment. Nonetheless, these 
studies may indicate that strong allergic responses are difficult to modify, regardless of 
treatment modality.24 From our data, we conclude that, in this pretreatment context, baseline 
component-resolved diagnosis does not add additional prognostic information above that 
offered by conventional peanut IgE measurements.
The higher Ara h 3-sIgE in failing subjects may reflect epitope spreading in those with a 
more severe phenotype,25 while the higher Ara h 8-sIgG4 may simply reflect the 
component’s cross-reactivity with the pollen pan-allergen, Bet v 1. It is also important to 
note that sIgE and sIgG4 values after 12 months of SLIT were not different in subjects 
passing or failing the challenge, indicating that using these time-of-challenge values would 
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not be useful in predicting whether subjects had become desensitized. This is in contrast to 
peanut-specific salivary IgA, which has been correlated with challenge outcomes following 
SLIT.8 Our findings regarding the predictive value of time-of-challenge immunoglobulin 
measurements are similar to two studies that examined subjects on both peanut OIT and 
SLIT, which also found these measurements to be non-significant between passing and 
failing groups.21,26 These studies also found that peanut OIT induced greater changes in 
peanut-specific IgE and IgG4 when compared to peanut SLIT, 21,26 but did not include 
component-specific measurements.
Overall, we found that Ara h 2- and peanut-specific IgE at baseline were best at determining 
those subjects which would pass a food challenge after 12 months of peanut SLIT. Lower 
IgE levels at the beginning of treatment was associated with SLIT desensitization, 
suggesting that an intervention with SLIT in younger children with lower peanut-specific 
IgE would be a worthwhile treatment approach. These findings are generally consistent with 
other published work demonstrating the immunodominance of Ara h 2 in American peanut-
allergic patients, and the inverse relationship between immunotherapy treatment outcomes 
and the strength of allergic priming. More study is necessary to identify robust 
immunotherapy-associated biomarkers.
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Figure 1. 
Peanut protein ingested during DBPCFC following 12 months of SLIT. 10 subjects passed 
the challenge by consuming 2500 mg without symptoms; 23 subjects failed the challenge. 
****p<0.0001. Lines represent medians.
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Figure 2. 
Component- and peanut-specific immunoglobulin data over time on treatment for all 
subjects. A) Specific IgE; B) Specific IgG4; C) Specific IgE/specific IgG4. *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001. Lines represent medians.
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Figure 3. 
Baseline component- and peanut-specific immunoglobulin data for subjects passing (P) and 
failing (F) the 12 month food challenge. A) Specific IgE; B) Specific IgG4; C) Specific IgE/
Specific IgG4. *p<0.05; **p<0.01; ****p<0.0001. Lines represent
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Figure 4. 
Receiver operating characteristic (ROC) curves for factors significantly different for groups 
passing and failing the 12 month food challenge. A) Superimposed ROC curves; B) Optimal 
cut points, area under the curve (AUC) and p-value for each curve.
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